NEJM This Week — July 16, 2026

A strong "less is more / right patient" issue. ENDURANCE shows that in standard-risk, transplant-ineligible myeloma, stopping lenalidomide at 2 years matches indefinite maintenance on survival — with less toxicity. DAPT-MVD finds extended dual antiplatelet therapy cuts ischemic events without extra bleeding, but only in a carefully selected multivessel, low-bleeding-risk group. ALLEGORY adds obinutuzumab as an effective B-cell-depleting option in active non-renal lupus. Two high-yield reviews — a practical fibromyalgia primer and a timely Bundibugyo virus outbreak review — plus a superb alpha-gal syndrome teaching case. The CDC's national HAI prevalence survey is summarized for awareness.

Heme / OncologyENDURANCE · RCTHigh yield · IM

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma

In standard-risk myeloma not undergoing up-front transplant, does indefinite vs fixed 2-year lenalidomide maintenance improve overall survival?

Population: 516 patients with standard-risk newly diagnosed multiple myeloma not receiving up-front autologous transplant, after proteasome-inhibitor–based 3-drug induction (KRd or VRd); high-risk cytogenetics excluded. ECOG-ACRIN open-label phase 3.
Intervention: Indefinite (continuous) lenalidomide 15 mg maintenance until progression.
Comparison: Fixed-duration lenalidomide for 2 years.
Outcome: No OS difference — 7-yr OS 68.6% vs 69.0% (diff −0.4 pp; 95% CI −9.0 to 8.3; P=0.93) at median 86-mo follow-up; median PFS 42.5 vs 38.9 mo (NS). Indefinite therapy caused more grade ≥3 nonhematologic toxicity (48.2% vs 31.5%) and more second primary cancers (11.2% vs 8.3%).

Clinical takeaway. In standard-risk transplant-ineligible myeloma after 3-drug induction, stopping lenalidomide at 2 years gives the same survival as indefinite maintenance with less toxicity and fewer second cancers. Per the editorial (Mian & Costa), this is a rare academically-driven "less is more" trial with one of the most mature maintenance datasets (86-mo follow-up); the no-benefit result held even though only ~35% achieved ≥CR, and likely extrapolates to more effective 4-drug/transplant regimens. What this changes: overturns the reflexive "maintain until progression" default and reframes future trials around treatment duration.

CardiologyDAPT-MVD · RCTHigh yield · IM

Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease

In multivessel CAD patients event-free 12 months after a drug-eluting stent, does an added 12 months of DAPT vs aspirin alone reduce ischemic events?

Population: 8250 patients, 18–75 yr, with multivessel CAD and no major ischemic or bleeding event during the first 12 months of DAPT after a drug-eluting stent; open-label, 97 centers in China.
Intervention: Additional 12 months of clopidogrel + aspirin.
Comparison: Aspirin monotherapy.
Outcome: CV death / nonfatal MI / nonfatal stroke lower with extended DAPT — 36-mo incidence 5.8% vs 6.8% (HR 0.82; 95% CI 0.69–0.98; P=0.03), driven by fewer non–target-vessel MIs. Clinically relevant or major bleeding (BARC ≥2) unchanged: 1.4% vs 1.5% (HR 0.89; P=0.54).

Clinical takeaway. By selecting a "high-ischemic, low-bleeding" phenotype (multivessel disease, age <75, already tolerated a year of DAPT), the trial decoupled ischemic benefit from bleeding harm — unlike the original DAPT trial, where the benefit came at a bleeding cost. Per the editorial (Park & Kang), generalizability is limited by an all-Chinese cohort (high CYP2C19 loss-of-function, low obesity), and the benefit may partly reflect clopidogrel's own efficacy (echoing HOST-EXAM); 5.8% still had a major ischemic event. What this changes: supports individualized, phenotype-based DAPT duration rather than a uniform 12-month stop.

RheumatologyALLEGORY · RCTHigh yield · IM

Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus

In active SLE without proliferative or membranous lupus nephritis, does adding obinutuzumab to standard therapy improve disease response?

Population: 303 adults with active SLE but without proliferative or membranous lupus nephritis, on standard therapy; phase 3, double-blind, placebo-controlled.
Intervention: Obinutuzumab 1000 mg IV on day 1 and weeks 2, 24, and 26 (glycoengineered type II anti-CD20).
Comparison: Placebo.
Outcome: Week-52 SRI-4 response 76.7% vs 53.5% (adjusted difference 23.1 pp; 95% CI 12.5–33.6; P<0.001); superior on all key secondary endpoints including sustained glucocorticoid reduction and time to first BILAG flare. Serious AEs 15.9% vs 11.9%; 1 vs 3 deaths.

Clinical takeaway. Obinutuzumab — a type II anti-CD20 antibody that depletes B cells more completely than rituximab — is effective in active non-renal SLE, extending its already-approved lupus-nephritis indication. A clean positive phase 3 adding a B-cell-depleting option to the SLE toolkit. What this changes: extends anti-CD20 depletion from lupus nephritis to non-renal active SLE; a likely new option pending approval.

RheumatologyReview · High yield · IM

Fibromyalgia (Clinical Practice)

What pain mechanism underlies fibromyalgia, and what is first-line versus harmful therapy?

•Fibromyalgia is nociplastic pain — CNS hypersensitization to painful and non-painful stimuli, not peripheral tissue damage — affecting 4–6% of adults (1.5–2× more women), with fatigue, poor sleep, and cognitive/sensory sensitivity. •Workup is context-dependent: minimal for long-standing, gradually evolving symptoms; broader for acute/subacute onset. •First-line care is education + physical activity + nonpharmacologic therapy (CBT, tai chi/yoga, mindfulness) — the most effective interventions. •Helpful drug classes: TCAs, gabapentinoids, and SNRIs (duloxetine). NSAIDs and opioids are not useful — opioids may be harmful.

Infectious DiseaseReview · High yield · ID

Bundibugyo Virus Disease in 2026 — Clinical and Public Health Responses

Where does Bundibugyo virus sit taxonomically, and what countermeasures exist?

•Bundibugyo virus is an orthoebolavirus (a filovirus / ebolavirus species) causing viral hemorrhagic fever, historically with lower case-fatality than Ebola (Zaire) or Sudan virus. •A 2026 outbreak in the DRC (Ituri Province) has already exceeded prior outbreaks in scale; genomics indicate a new zoonotic spillover. •There is no licensed Bundibugyo-specific vaccine or therapeutic; Ebola-virus vaccines and monoclonal antibodies may be cross-protective (nonhuman-primate/serologic data, unproven). •Control rests on supportive care plus classic outbreak measures: rapid case detection, lab confirmation, isolation, contact tracing, HCW protection, and community engagement.

Teaching Case · Case Records of the MGH

Case 20-2026: A 38-Year-Old Man with Abdominal Pain · Infectious Disease / Allergy

High yield · IM/ID

Key learning point. Final diagnosis: alpha-gal syndrome — IgE to galactose-α-1,3-galactose acquired from lone star tick (Amblyomma americanum) bites. Reactions are delayed 1–6 hours after mammalian meat or gelatin (the glycolipid allergen must first be digested), distinguishing it from immediate IgE food allergy, and can be GI-predominant without urticaria (± eosinophilia, as here). Diagnose with serum alpha-gal IgE (13.10 kU/L; reference <0.10). Manage by avoiding mammalian meat and gelatin — including gelatin capsules, heparin, some vaccines, antivenom, and cetuximab — with epinephrine available for anaphylaxis; the IgE level and symptoms fall with avoidance.

Also in this issue. Original Article (observational — summarized, not carded) — Health Care–Associated Infections in U.S. Hospitals, 2023 vs 2015: CDC Emerging Infections Program point-prevalence survey; HAI prevalence fell to 2.6% (1 of 38 patients) in 2023 vs 3.2% in 2015 (adjusted RR 0.73; 95% CI 0.63–0.85), ~60% of HAIs were not device- or procedure-associated, and the estimated national burden was ~518,000 HAIs in 2023. Perspectives — caring for undocumented patients; public–private health-information collaboration; pharmacotherapy decisions in autism; "The Symptom Tracker". Images in Clinical Medicine — lead lines in severe lead poisoning; descending thoracic aortic aneurysm. Correspondence — UAE premarital genetic screening; NET degradation in DNASE1L3-deficient lupus; fish-oil supplementation and CV events in hemodialysis.

Summaries are original paraphrases prepared for educational use; figures are drawn from the published full text. Read the full articles at NEJM.org (subscription required). Trial registrations: ENDURANCE (NCT01863550), DAPT-MVD (NCT04624854), ALLEGORY (NCT04963296). Citations: N Engl J Med 2026; Vol. 395, No. 3. DOIs: 10.1056/NEJMoa2600157 (editorial 10.1056/NEJMe2604761), 10.1056/NEJMoa2517588 (editorial 10.1056/NEJMe2604885), 10.1056/NEJMoa2516150, 10.1056/NEJMoa2510881, 10.1056/NEJMcp2411656, 10.1056/NEJMra2607216, 10.1056/NEJMcpc2513544.